Biotechnology - Medivation


Current filters:


Popular Filters

Promising emerging agents for triple negative breast cancer


Due to the heterogeneity of triple negative breast cancer, the most promising emerging agents in development…

Astellas PharmaBiotechnologyMarkets & MarketingMedivationniraparibOncologyTesaroXtandi

FDA backs Medivation and Astellas' prostate cancer drug Xtandi


USA-based Medivation (Nasdaq: MDVN and Japanese drug major Astellas Pharma (TYO: 4503) say that the US…

Astellas PharmaBiotechnologyenzalutamideMedivationNorth AmericaOncologyPharmaceuticalRegulationXtandi

Expanded Access Program for enzalutamide agreed with US FDA


The US Food and Drug Administration agreed that Medivation (Nasdaq: MDVN) and Japanese drug major Astellas…

Astellas PharmaBiotechnologyenzalutamideMDV3100MedivationNorth AmericaOncologyPharmaceuticalRegulation

Emerging therapies will drive prostate cancer drug market to $10.1 billion in 2020


Driven by the launches of several promising emerging therapies, the prostate cancer drug market will…

Astellas PharmaBiotechnologyGlobalJohnson & JohnsonMarkets & MarketingMedivationOncologyPharmaceuticalZytiga

Back to top